Back to research

Research paper

Autism spectrum disorder comorbid with epilepsy: Etiology, mechanism, and therapy

Neural Regeneration Research 2026 comprehensive review of ASD-epilepsy comorbidity. Covers genetic and environmental etiologies, E/I imbalance as core mechanism (GABAergic/glutamatergic), astrocyte dysfunction, maternal immune activation, and integrated etiology-mechanism-treatment clinical approach. Recommends integrating pharmacotherapy (with CBD showing promise), neurostimulation (DBS/VNS/TMS), dietary therapy, and immunotherapy.

Indexed context

Shan M, et al.

autismepilepsycomorbiditye-i-balancegabaergicglutamatergicastrocytecbdreview2026

Markdown path

content/research/papers/2026-shan-asd-epilepsy-comorbidity-nrr.md

Findings

Neural Regeneration Research 2026 comprehensive review of ASD-epilepsy comorbidity. Covers genetic and environmental etiologies, E/I imbalance as core mechanism (GABAergic/glutamatergic), astrocyte dysfunction, maternal immune activation, and integrated etiology-mechanism-treatment clinical approach. Recommends integrating pharmacotherapy (with CBD showing promise), neurostimulation (DBS/VNS/TMS), dietary therapy, and immunotherapy.

Why it may matter for Levi

Consolidates multiple therapeutic axes under a single etiology-mechanism-treatment framework that fits Levi's multi-axis picture (DEE-SWAS + ASD + immune signal + overgrowth). Astrocyte-dysfunction framing is novel in this corpus; opens a mechanistic thread worth tracking if future imaging or biomarkers show astrocytic injury signatures (GFAP - per Butera 2026).

Paper text

Shan et al. (2026) — ASD comorbid with epilepsy review

Source

  • Neural Regeneration Research, 2026.

Why in corpus

Comprehensive 2026 review of the mechanisms underlying ASD-epilepsy comorbidity — complements Zahra 2022 already in the corpus with updated 2026 synthesis and explicit clinical approach model.

Key findings

  • Genetic causes: gene mutations, CNVs, SNPs.
  • Environmental factors: imbalanced nutrient intake, prenatal exposure to sodium valproate.
  • Core mechanism: E/I imbalance, primarily involving GABAergic and glutamatergic systems.
  • Astrocyte dysfunction exacerbates E/I imbalance.
  • Immunological mechanisms: maternal immune activation as key environmental factor.
  • Recommends clinical approach based on "etiology-mechanism-treatment" model, integrating pharmacotherapy (with CBD showing promise), neurostimulation (DBS, VNS, TMS), dietary therapy, and immunotherapy.

Levi-relevant takeaways

  • Consolidates multiple therapeutic axes (pharmacotherapy, neuromodulation, dietary, immunotherapy) under a single etiology-mechanism-treatment framework that fits Levi's multi-axis picture (DEE-SWAS + ASD + immune signal + overgrowth).
  • CBD mentioned specifically — consistent with Gaston 2021 and Datta 2026 already in the corpus as a contingent option with multi-axis rationale.
  • The astrocyte-dysfunction framing is novel in this corpus; opens a mechanistic thread worth tracking if future Levi imaging or biomarkers show astrocytic injury signatures (GFAP — per Butera 2026).
  • Reinforces the broader case for integrated multidisciplinary care rather than treating epilepsy and ASD as separate problems.